Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Impact · against what's priced in

Avalo Therapeutics shows positive clinical momentum and a strong balance sheet, but the article offers no new catalysts beyond existing expectations. The primary valuation driver remains the future Phase 3 results for abdakibart, which are not yet delivered.

AVTX+0.40: No priced-in read yet
In context: The positive LOTUS results and monthly dosing schedule for abdakibart provide a competitive clinical profile, supported by a cash runway sufficient to reach upcoming milestones.
Read from the article alone

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

clinical trials▲111%
biotech▲23%
healthcare
AVTX
balance sheet
drug development
pivotal trial

Top 2 movers · tap to explore

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

What matters in this story

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

What matters in this story

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

How each ticker is affected

Track these names every morning.

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

What matters in this story

Next reads from the same story arc

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

What matters in this story

Next reads from the same story arc

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

How each ticker is affected

Track these names every morning.

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer